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ABSTRACT Antimicrobial-resistant (AMR) infections pose a serious risk to human and
animal health. A major factor contributing to this global crisis is the sharing of resistance
genes between different bacteria via plasmids. The WHO lists Enterobacteriaceae, such as
Escherichia coli and Klebsiella pneumoniae, producing extended-spectrum -lactamases
(ESBL) and carbapenemases as “critical” priorities for new drug development. These re-
sistance genes are most often shared via plasmid transfer. However, finding methods to
prevent resistance gene sharing has been hampered by the lack of screening systems
for medium-/high-throughput approaches. Here, we have used an ESBL-producing plas-
mid, pCT, and a carbapenemase-producing plasmid, pKpQIL, in two different Gram-
negative bacteria, E. coli and K. pneumoniae. Using these critical resistance-pathogen
combinations, we developed an assay using fluorescent proteins, flow cytometry, and
confocal microscopy to assess plasmid transmission inhibition within bacterial popula-
tions in a medium-throughput manner. Three compounds with some reports of antiplas-
mid properties were tested; chlorpromazine reduced transmission of both plasmids and
linoleic acid reduced transmission of pCT. We screened the Prestwick library of over
1,200 FDA-approved drugs/compounds. From this, we found two nucleoside analogue
drugs used to treat HIV, abacavir and azidothymidine (AZT), which reduced plasmid
transmission (AZT, e.g., at 0.25g/ml reduced pCT transmission in E. coli by 83.3% and
pKpQIL transmission in K. pneumoniae by 80.8% compared to untreated controls). Plas-
mid transmission was reduced by concentrations of the drugs which are below peak se-
rum concentrations and are achievable in the gastrointestinal tract. These drugs could
be used to decolonize humans, animals, or the environment from AMR plasmids.
IMPORTANCE More and more bacterial infections are becoming resistant to antibi-
otics. This has made treatment of many infections very difficult. One of the reasons
this is such a large problem is that bacteria are able to share their genetic material
with other bacteria, and these shared genes often include resistance to a variety of
antibiotics, including some of our drugs of last resort. We are addressing this prob-
lem by using a fluorescence-based system to search for drugs that will stop bacteria
from sharing resistance genes. We uncovered a new role for two drugs used to treat
HIV and show that they are able to prevent the sharing of two different types of re-
sistance genes in two unique bacterial strains. This work lays the foundation for fu-
ture work to reduce the prevalence of resistant infections.
KEYWORDS antimicrobial resistance, E. coli, K. pneumoniae, ESBL, carbapenemases,
KPC, CTX-M, carbapenemase
The threat of untreatable infections due to antimicrobial resistance (AMR) has beenrecognized by global agencies, including the World Health Organization (WHO),
and national governments (1–3). A key factor contributing to AMR is mobile genetic
Citation Buckner MMC, Ciusa ML, Meek RW,
Moorey AR, McCallum GE, Prentice EL, Reid JP,
Alderwick LJ, Di Maio A, Piddock LJV. 2020. HIV
drugs inhibit transfer of plasmids carrying
extended-spectrum β-lactamase and
carbapenemase genes. mBio 11:e03355-19.
https://doi.org/10.1128/mBio.03355-19.
Editor Julian E. Davies, University of British
Columbia
Copyright © 2020 Buckner et al. This is an
open-access article distributed under the terms
of the Creative Commons Attribution 4.0
International license.
Address correspondence to Michelle M. C.
Buckner, m.buckner@bham.ac.uk.
* Present address: Richard W. Meek, York
Structural Biology Laboratory, Department of
Chemistry, University of York, York, United
Kingdom.
This article is a direct contribution from Laura
Jane Violet Piddock, a Fellow of the American
Academy of Microbiology, who arranged for
and secured reviews by Barry Kreiswirth,
Rutgers New Jersey Medical School, and Teresa
Coque, Hospital Universitario Ramón y Cajal.
Received 7 January 2020
Accepted 10 January 2020
Published
RESEARCH ARTICLE
Therapeutics and Prevention
crossm
January/February 2020 Volume 11 Issue 1 e03355-19 ® mbio.asm.org 1
25 February 2020
 o
n
 M
ay 18, 2020 by guest
http://m
bio.asm
.org/
D
ow
nloaded from
 
elements such as plasmids, which can carry multiple antimicrobial resistance genes
(ARGs) and are commonly found within the order Enterobacteriales (which consists of
one family, Enterobacteriaceae), including many difficult-to-treat species such as
multidrug-resistant (MDR) Escherichia coli and Klebsiella pneumoniae. In particular,
plasmids increasingly carry ARGs coding for proteins such as extended-spectrum
-lactamases (ESBLs; e.g., CTX-M), carbapenemases (e.g., KPC), and colistin resistance
proteins (e.g., MCR-1) (4–6). The WHO lists carbapenem-resistant and ESBL-producing
Enterobacteriaceae as a critical priority for which new drugs are needed (7), and the CDC
lists them as an urgent and serious threat, respectively (8). Therefore, finding new
strategies to combat ESBL- and carbapenemase-producing Enterobacteriaceae is of the
utmost importance.
These bacteria have proven particularly difficult to treat for a few key reasons; one
is that the genes coding for ESBLs and carbapenemases are most often carried on
plasmids, most of which are conjugative. These AMR plasmids and ARGs are found
within, and shared between, bacteria colocalizing the same niche, such as intestinal
tracts (9–11); environments, including wastewater and river sediments (12); agricultural
soil (13–15); and hospital surfaces (16, 17). Furthermore, ARGs frequently located on
plasmids have been acquired by people traveling to areas of the world with high levels
of AMR (18–20). With the single acquisition of an MDR, ESBL- or carbapenemase-
producing plasmid, Enterobacteriales can go from being easily treatable to extremely
challenging. Therefore, AMR plasmids pose a serious risk to human and animal health.
One example of a highly successful AMR plasmid is the IncK plasmid pCT, which
carries a group 9 blaCTX-M-14 ESBL gene (5). pCT-like elements have been found in
commensal and extraintestinal pathogenic E. coli isolates from humans and animals (21,
22). The CTX-M family is the largest group of ESBLs (23). blaCTX-M-14 is the most
commonly found ESBL gene in parts of Asia and Spain (23). IncK plasmids in particular
have contributed to the spread of blaCTX-M-14 in Spain (24) and the United Kingdom
(25). The high rate of pCT conjugation and high degree of stability have contributed to
the spread of pCT-like plasmids among diverse E. coli strains (21, 26, 27). E. coli from the
ST131 clonal group is globally the most predominant cause of extraintestinal E. coli
infections, such as urinary tract infections (UTIs), and has been associated with the
success of some blaCTX-M genes such as blaCTX-M-15 (23, 28, 29).
Likewise, the carbapenemase-producing plasmid pKpQIL and its variants have been
isolated around the world in a variety of species but are predominantly found in K.
pneumoniae (30–33). The prevalence and spread of pKpQIL in the United Kingdom have
been well characterized (6, 34–38). pKpQIL is a 114-kb, IncFIIK2 plasmid carrying the
blaKPC carbapenemase gene, the blaTEM -lactamase gene, and heavy metal resistance
and is self-transmissible (30, 39, 40). pKpQIL is well adapted to the K. pneumoniae host
and is stably maintained in K. pneumoniae populations (31, 38).
One approach to tackling ESBL- and carbapenemase-producing Enterobacteriales is
to reduce the prevalence of AMR plasmids, by decolonization of people, animals,
and/or the environment. Antiplasmid compounds can act by reducing plasmid stability,
resulting in eradication of plasmids from a population (termed plasmid curing), and/or
preventing transmission of a plasmid to a new host (41, 42). Except for a few such as
chlorpromazine, ascorbic acid, and linoleic acid, most compounds identified since the
1960s with reported antiplasmid activity are toxic to humans (42). Chlorpromazine
belongs to the phenothiazine class of antipsychotic drugs (43, 44). However, the
literature regarding the plasmid curing ability of chlorpromazine is controversial, and
there are inconsistent reports of activity. Ascorbic acid (vitamin C) cured Gram-positive
bacteria (Staphylococcus aureus and Pediococcus acidilactici) of some drug resistance
plasmids (45–47). However, the impact upon clinically relevant Gram-negative
bacterium-plasmid host combinations is unclear. The unsaturated fatty acid linoleic
acid inhibited conjugation of some plasmids in E. coli (48) by inhibiting the activity of
the TwrD ATPase (VirB11 homologue), which is involved in the conjugative machinery
required for transmission (49). However, none of these compounds have been tested
on pCT or pKpQIL.
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In order to discover safe and efficacious ways to remove and/or prevent the spread
of ESBL- and carbapenemase-producing plasmids from Enterobacteriales, we have
developed a method to monitor transmission of pCT and pKpQIL in real time using
fluorescent protein genes on both the plasmids and host strains E. coli ST131 (50–52)
and K. pneumoniae Ecl8 (38, 53, 54). Plasmid dynamics within the bacterial population
were monitored using flow cytometry and microscopy. We demonstrate that chlor-
promazine reduced pCT and pKpQIL transmission, while linoleic acid inhibited only
pCT, and ascorbic acid had little impact. This assay was then used in a medium-
throughput screen (MTS) of the Prestwick FDA-approved library. We identified a novel
role as antiplasmid compounds for two FDA-approved anti-HIV drugs, abacavir and
azidothymidine (AZT; also called zidovudine), which reduced transmission of both the
ESBL- and carbapenemase-producing plasmids in E. coli and K. pneumoniae. We also
demonstrated the activity of these novel antiplasmid compounds at clinically achiev-
able concentrations and at which they do not impact bacterial growth, and so the
likelihood of selective pressure for the emergence of transmission-inhibitor resistance
is minimal.
RESULTS
Development of assay to measure plasmid transmission in a bacterial popu-
lation. In order to rapidly measure the dynamics of pCT and pKpQIL transfer to host
strains, fluorescence-based reporters were constructed in E. coli ST131 EC958 (clade C)
and K. pneumoniae Ecl8, respectively. Prior to insertion of pCT into ST131 EC958, the
resident plasmid (pEC958) (55) was removed using an incompatibility-based system (for
additional detail, see Text S1 and Fig. S1a in the supplemental material).
The gfp gene was inserted into pCTCTX-M-14, giving pCTgfp, which was transferred by
conjugation into ST131c, forming ST131c pCTgfp. In order to monitor pKpQIL in K.
pneumoniae, the gfp gene was inserted into the blaKPC locus in pKpQIL, thus disrupting
the blaKPC gene and resulting in pKpQILgfp. Conjugation was used to insert pKpQILgfp
into K. pneumoniae strain Ecl8, forming Ecl8 pKpQILgfp. These strains formed the
plasmid donors. The recipient strains were constructed by inserting mcherry into the
putPA intergenic region, as per reference 56, in the chromosome of ST131c, thus
forming ST131c mcherry, and of Ecl8, forming Ecl8 mcherry. Strains were confirmed by
PCR and DNA sequencing (see Text S1 and Tables S4 to S6), and flow cytometry was
used to confirm expression of fluorescent proteins (Fig. 1a). Plasmid transmission was
measured by flow cytometry, which quantified the number of green fluorescent protein
(GFP)-positive bacteria (donors), mCherry-positive bacteria (recipients), and GFP-
positive/mCherry-positive bacteria (transconjugants) (Fig. 1b).
Since fluorescent proteins were used as an indicator of plasmid transmission,
confocal microscopy was used to monitor plasmid transmission. Images of E. coli/
pCTgfp donor and E. coli mcherry recipient strains were collected at time zero, prior to
transmission (Fig. 2a, top panel), and at 120 min, which was sufficient time for
transmission events to occur and with transconjugant bacteria clearly visible (Fig. 2a,
bottom panel). A time course was performed with the same strains by taking images
every 10 min up to 120 min. During this time lapse, donor and recipient bacteria
coming into close contact were captured at 60 and 90 min, as well as a transconjugant
bacterium expressing both green and red fluorescent proteins at 120 min (Fig. 2b). Over
120 min, the number of colocalization events (defined as GFP/mCherry pixels) was
calculated and compared. An increase in the number of colocalization events was
visible over time (from 0% to 0.13% of events, Fig. S1b). This indicates that plasmid
transmission occurs rapidly and can be monitored by the fluorescent system.
Plasmid transmission is impacted by the ratio of donor and recipient bacteria.
The ratio of donor to recipient cells is known to impact the transfer efficiency of
plasmids (57–59). Therefore, we used flow cytometry to measure the number
of transconjugant/transconjugant daughter cells in a population after coincubation of
donors and recipients at a range of donor-to-recipient ratios and time points. All
bacteria were adjusted to an optical density of 0.5 at 600 nm (OD600) prior to
Compounds Reduce AMR Plasmid Transmission ®
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conjugation experiments. For pCTgfp in E. coli, the highest number of transconjugants
was observed after 24 h between ratios of 1:1 and 6:1 (Fig. 3a), with the number of
transconjugants between 25 and 30% of cells. Based on these data, the optimal
transmission ratio of 3 donor to 1 recipient was chosen for further experiments. To
determine the optimal time point, transmission was measured every hour for 12 h and
at 24 h using the 3:1 donor/recipient ratio. The level of transmission increased over
time, with maximal numbers of transconjugants obtained between 11 and 24 h of
coincubation (Fig. 3b).
For pKpQILgfp transmission in K. pneumoniae, after 6 h the number of transconju-
gants peaked between the ratios of 1:8 and 1:2 (Fig. 3c). Ratios between 1:1 and 8:1
resulted in a sequential reduction in transconjugant populations (Fig. 3c). The ratio of
1:2 was selected for further experiments. The number of transconjugants produced was
monitored at three time points: 4, 6, and 24 h. There was little change in the number
of transconjugants between 4 and 24 h (Fig. 3d). Six hours was chosen for further
experiments because at 24 h evidence of biofilm formation was observed, which is
known to impact plasmid transmission (60–62).
Effect of known plasmid-transmission inhibitors upon transmission of pCT and
pKpQIL into E. coli and K. pneumoniae, respectively. (i) Chlorpromazine. Chlor-
promazine reduced transmission of both plasmids in both strains. For pCTgfp trans-
mission in E. coli, after 24-h exposure concentrations of chlorpromazine of 20 g/ml
significantly reduced transmission (P 0.001, Fig. 4a). The MIC of chlorpromazine was
128 g/ml for all E. coli strains (Table 1). While the concentrations that inhibited
transmission were below the MIC, we wanted to determine if chlorpromazine inhibited
bacterial growth (as this may impact the composition of the population). Therefore,
growth rate was determined in the presence of 30 g/ml chlorpromazine. Some degree
of growth inhibition was indicated by an increase in the generation time from 66 
8 min to 87  10 min for ST131c, 75  16 min to 96  18 min for ST131 mcherry, and
FIG 1 (a) Representative flow cytometry plots of ST131c EC958 pCTgfp (top) and ST131c EC958 mcherry (bottom). For each, 10,000 bacterial events were collected
and are displayed in each plot. (b) Diagrammatic representation of transmission detection system using fluorescent markers. (Panel 1) Donor strains express gfp
constitutively from the plasmid, while recipient strains expressmcherry constitutively from the chromosome. (Panel 2) Conjugative transmission event occurs between
donor and recipient strains. (Panel 3) Newly formed transconjugant expresses both gfp (plasmid) and mcherry (chromosome). (Bottom) Transmission experiment 24 h
after combination of donor and recipient bacteria, with transconjugant bacteria (TC) indicated in purple square gate.
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77  20 min to 93  14 min for ST131c pCTgfp. Additional growth kinetic experiments
revealed that a chlorpromazine concentration of 20 g/ml had no impact upon growth
rate of E. coli ST131 EC958 derivatives (Fig. S2a). Furthermore, 20 g/ml chlorpromazine
still reduced pCTgfp transmission (Fig. 4a).
Concentrations of 50 g/ml chlorpromazine resulted in a significant reduction in
K. pneumoniae pKpQILgfp transconjugants (Fig. 4b). The MIC of chlorpromazine for
these strains was 256 g/ml (Table 1). As with E. coli, 20 g/ml chlorpromazine had no
effect upon bacterial growth (Fig. S2b); however, this concentration did not reduce
pKpQIL transconjugants. The concentration range that we tested goes above the peak
serum concentrations of chlorpromazine (0.1 g/ml) (63). We aimed to test concentra-
tions of compounds that were within the therapeutic window. However, for some
compounds such as chlorpromazine, only at higher concentrations were effects seen on
bacterial plasmid transmission.
In order to validate the flow cytometry data, classical conjugation experiments with
E. coli were performed. To enable these experiments, a rifampin-resistant recipient
strain of ST131c was generated; PCR and sequencing indicated a mutation resulting in
the substitution H537Y in the rpoB product. The MIC of rifampin for the wild type was
8 g/ml and for the mutant was 1,024 g/ml. The impact of chlorpromazine upon
pCTgfp transmission was tested in liquid mating experiments, and the data obtained
confirmed the results obtained by flow cytometry. In 20 g/ml chlorpromazine, there
was an 82% reduction in transconjugants compared to LB alone (Table 2). While the
growth rate of the bacterial strains in 20 g/ml chlorpromazine was unaffected, a
2.8-fold reduction in the viable counts of total bacteria after the classical conjugation
assay was seen. This supported the hypothesis that chlorpromazine inhibits bacterial
growth.
(ii) Linoleic acid. The unsaturated fatty acid linoleic acid was tested for inhibition of
plasmid transmission. For E. coli, between 3 and 6 mM linoleic acid effectively reduced
transmission of pCTgfp at 24 h (3 and 5 mM, P 0.05; 4 and 6 mM, P 0.001) (Fig. 4c).
The MIC of linoleic acid was 512 mM for all strains (Table 1); 6 mM linoleic acid had
no effect upon growth of the ST131c strains (Fig. S2a). Estimates for the normal serum
levels of linoleic acid in healthy individuals vary between studies but are in the range
of 0.2 to 5.0 mM (64, 65). The classical conjugation assays confirmed a 99% reduction
FIG 2 Confocal microscopy images of pCT transmission in MOPS minimal medium. (a) pCT transmission at time
zero and 120 min. (b) Microscopy time course, showing a GFP bacterium interacting with an mCherry bacterium
60 and 90 min after mixing; then, at 120 min the GFP/mCherry bacterium is present.
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in transconjugants compared to LB alone (Table 2), without impacting the viable counts
of either ST131c pCTgfp or ST131c mcherry.
For pKpQILgfp transconjugants in K. pneumoniae, at 0.5 and 1 mM linoleic acid
increased the number of transconjugants at 6 h (P 0.047 and 0.001, respectively;
Fig. 4d). No reduction in transconjugants was observed at any concentration tested.
These concentrations are within the range which reduces transmission of other
plasmids (48), including pCT (Fig. 4c), and are well below the MIC of linoleic acid
(512 mM, Table 1); 6 mM linoleic acid had no impact upon bacterial generation
time (Fig. S2b).
(iii) Ascorbic acid. Ascorbic acid had no detectable impact on pCTgfp transmission
in E. coli ST131c at any concentration when tested by flow cytometry up to the 24-h
endpoint (Fig. 4e). However, ascorbic acid reduced the number of transconjugants
when tested in a classical conjugation experiment (50% reduction [Table 2]). In order to
identify antiplasmid activity of ascorbic acid, a concentration range at and above the
upper peak serum concentration was used. The maximum concentration tested
(3.5 mg/ml) was just below the MIC of ascorbic acid, 4 mg/ml (Table 1), and this
concentration inhibited growth (increased the generation time of all strains [Fig. S2a])
and is above the peak serum concentration after intravenous (i.v.) treatment (2.4 mg/
ml) (66). Ascorbic acid had no impact upon transmission of pKpQIL in K. pneumoniae
(Fig. 4f), even at the high and growth-inhibiting concentration of 3.5 mg/ml; the MIC of
ascorbic acid is 4 to 8 mg/ml (Table 1; Fig. S2b).
An ESBL-free ST131 clinical isolate shows a similar pCT transmission profile as
EC958. To ensure that data obtained with E. coli ST131 EC958, which had been cured
of its original plasmid, were not atypical, the effect of the antiplasmid compounds upon
pCT transmission in a human clinical isolate of E. coli ST131 B104 with no identified
plasmids (52) was measured. Both EC958 and B104 belong to ST131 clade C (52). For
FIG 3 Measuring transmission using flow cytometry. (a) The impact of altering the ratio of donor to recipient E.
coli on the amount of pCTgfp transconjugant bacteria (GFP/mCherry) after 24 h of coincubation. (b) E. coli
pCTgfp transconjugants over time, mixed in a 3:1 donor/recipient ratio. (c) The impact of altering the ratio of donor
to recipient K. pneumoniae on the amount of pKpQILgfp transconjugant bacteria (GFP/mCherry) after 6 h of
coincubation. (d) Transmission of pKpQILgfp in K. pneumoniae at 4, 6, and 24 h after combination of donor and
recipient in a 1:2 ratio. Data show the mean from three independent experiments composed of three biological
replicates  standard deviation.
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B104, a donor-to-recipient ratio of 3:1 resulted in the most consistent and highest
average proportion of transconjugants (Fig. 5a). These data are similar to those for
pCTgfp transmission in ST131c. This ratio was therefore used for further experiments.
Linoleic acid (6 mM) and chlorpromazine (20 g/ml) both significantly reduced the
number of transmission events at 24 h (P 0.001, Fig. 5b). The compounds had no
effect on the growth of the strains (Fig. S2c). Overall, the data obtained were similar to
those obtained for ST131c. Interestingly, ascorbic acid, which had no impact on pCTgfp
transmission in ST131c, reduced transmission in B104 by 19% compared to LB alone
(P 0.05, Fig. 5b).
Medium-throughput screening of the Prestwick library identified two FDA
approved drugs with antiplasmid activity in both E. coli and K. pneumoniae. The
FIG 4 Dose response for the activity of antiplasmid compounds on plasmid transmission compared to
LB alone. (a) The impact of chlorpromazine on pCTgfp transmission in E. coli after 24-h incubation. (b) The
impact of chlorpromazine on pKpQILgfp transmission in K. pneumoniae after 6-h incubation. (c) The
impact of linoleic acid (LA) on pCTgfp transmission in E. coli after 24-h incubation. (d) The impact of
linoleic acid on pKpQILgfp transmission in K. pneumoniae after 6-h incubation. (e) The impact of ascorbic
acid (AA) on pCTgfp transmission in E. coli after 24-h incubation. (d) The impact of ascorbic acid on
pKpQILgfp transmission in K. pneumoniae after 6-h incubation. Data show the mean standard deviation
from a minimum of three independent experiments, each with a minimum of three biological replicates.
*, P 0.05; **, P 0.001.
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flow cytometry assay was used to screen the Prestwick Chemical Library comprising
1,280 molecules containing mostly approved drugs (FDA, European Medicines
Agency [EMEA], and other agencies) selected for their high chemical and pharma-
cological diversity. This library was screened at 10 M for compounds which reduce
AMR plasmid transmission. From the screen results, all compounds known to be
antibacterials or biocides were removed from the hit list, along with compounds
which had a significant impact upon growth of bacteria (as measured by OD600 after
incubation). These criteria reduced the number of hits to seven compounds:
dexamethasone acetate, atropine sulfate monohydrate, abacavir sulfate, flavoxate
hydrochloride, zidovudine (AZT), dolasetron mesylate, and pramipexole. Dexameth-
asone acetate was removed from the list as bacteria exposed to this compound
produced very weak fluorescent signals. We decided to focus on two hits, abacavir
and AZT, because they belong to the same class of drugs and they demonstrated
promising results in three independent screening experiments for inhibition of
transmission of both pCT and pKpQIL.
(i) Abacavir. Abacavir did not inhibit growth of any bacterial strain (MIC of
512 g/ml, Table 1), and 32 g/ml of abacavir had no effect on the growth of any
strain (Fig. S2a and b). To determine the optimal concentration for transmission
TABLE 1MICs of antibiotics and compounds
Strain
MIC of drug:
Kanamycin
(g/ml)a
Ampicillin
(g/ml)a
Cefotaxime
(g/ml)a
Nalidixic
acid (g/ml)b
Linoleic
acid (mM)c
Ascorbic
acid (mg/ml)c
Chlorpromazine
(g/ml)c
Abacavir
(g/ml)c
AZT
(g/ml)c
E. coli
ST131 32 128 256 256 512 8 128 512 NDd
ST131 pCure 4 0.5 4 256 ND ND ND ND ND
ST131c 4 0.5 4 256 512 8 128 512 4
ST131c mcherry ND ND ND ND 512 8 128 512 4
ST131c pCTgfp ND ND ND ND 512 8 128 512 2
ST131 B104 4 ND ND ND 512 8 128 512 ND
ST131 B104 mcherry ND ND ND ND 512 8 128 512 ND
ST131 B104 pCTgfp ND ND ND ND 512 8 128 512 ND
ST131c mcherry
AZT-resistant
mutant
ND ND ND ND ND ND ND ND 32
ST131c pCTgfp
AZT-resistant
mutant
ND ND ND ND ND ND ND ND 32
K. pneumoniae
Ecl8 ND ND ND 2 512 8 256 512 2–4
Ecl8 pKpQILgfp ND ND ND ND 512 8 256 512 2–4
Ecl8 mcherry ND ND ND ND 512 4 256 512 8–16
Ecl8 Nalr ND ND ND 256 ND ND ND ND ND
aThe resistance to these antibiotics is encoded on the pEC958 plasmid.
bThe resistance to this antibiotic is encoded on the ST131 EC958 chromosome.
cAntiplasmid compounds.
dND indicates that data were not required and so not determined.
TABLE 2 Conjugation frequencies of pCTgfp from ST131 EC958 pCTgfp into ST131c in the presence of ascorbic acid (3.5 mg/ml), linoleic
acid (6 mM), chlorpromazine (20 g/ml), abacavir (8 g/ml), or AZT (0.008 g/ml)a
Compound
Conjugation frequency
in compound ( SD)
Corresponding conjugation
frequency in LB control ( SD)
% conjugation compared
to LB control
Ascorbic acid 5.62  108  9.47  108 1.15  107  2.24  107 49
Linoleic acid 8.48  1010  3.28  1010 1.15  107  2.24  107 0.74
Chlorpromazine 4.24  108  2.53  108 2.32  107  1.74  107 18
Abacavir 6.22  107  2.90  107 4.61  107  2.55  107 135
AZT 2.34  107  6.16  108 3.25  107  1.39  107 72
aData are the averages from three independent experiments, carried out with a minimum of three biological replicates each. Corresponding conjugation frequency in
LB control represents frequency for the particular set of three independent experiments.
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inhibition, dose-response curves with abacavir were performed using flow cytometry.
These demonstrated significant reduction of pCTgfp transmission in ST131c at 8 g/ml
abacavir (85.4% of the LB controls, P 0.01) (Fig. 6a). Interestingly, 16 g/ml had no
impact on pCTgfp transmission (Fig. 6a). For E. coli ST131 B104, 16 g/ml abacavir
resulted in a significant reduction of pCTgfp transmission (85% of LB controls,
P 0.0036) (Fig. S3). Concentrations of 32 g/ml abacavir affected recipient strain
growth (data not shown). Classical conjugation assays showed that 8 g/ml abacavir
increased the number of transconjugants by 135% (Table 2). Abacavir is a well-
characterized drug, and concentrations reached in the serum of patients being treated
for HIV are typically 3 g/ml (Table S1).
At 2 to 16 g/ml, abacavir also reduced the number of pKpQILgfp transconjugants;
the largest reduction was seen at 16 g/ml abacavir (77.4% of LB controls, P 0.001)
(Fig. 6b). To carry out a classical conjugation experiment, we generated a nalidixic
acid-resistant mutant to act as the recipient strain; this allowed transconjugant bacteria
to be distinguished by plating on a combination of kanamycin and nalidixic acid.
Sequencing demonstrated an S83F mutation in gyrA, and the MIC of nalidixic acid for this
strain was 256g/ml (Table 1). These mating experiments confirmed our flow cytometry
data: 16g/ml abacavir resulted in a reduction in conjugation frequency to 63.0% 23.1%
of LB controls (P 0.0498; abacavir conjugation frequency, 1.58 105  6.39 106; LB
conjugation frequency, 2.88 105  1.62 105).
(ii) AZT. AZT was also identified in our MTS experiments. Using flow cytometry, AZT
caused a substantial, highly significant, and dose-dependent reduction in pCT trans-
mission in E. coli (Fig. 6c); even the lowest concentration of AZT tested (0.008 g/ml)
resulted in a 52.4% reduction compared to LB alone (P 0.0067); 0.25 g/ml AZT
reduced transconjugants by 83.3%  4.9% of LB controls (P 0.0001). An AZT con-
centration of 0.008 g/ml is between 1/512 and 1/256 the MIC of AZT for both strains
(Table 1). As other studies have examined the antimicrobial activity of AZT (67–71), we
also examined the impact of sub-MICs of AZT on bacterial growth. With increasing AZT
concentrations, there was an increase in the generation time; at 0.008 g/ml there was
no effect on bacterial growth (Fig. S2d and e). This is well below peak serum concen-
trations, which range between 0.05 and 1.46 g/ml (Table S1) (72). Together, this shows
a concentration of AZT which reduces transmission of pCT by 	50% and has no effect
on bacterial growth. Supporting this, the classical conjugation experiments revealed
that at 0.008 g/ml, the conjugation frequency with AZT was 28% lower than the
conjugation frequency in LB alone (Table 2).
FIG 5 pCTgfp transmission dynamics in ST131 strain B104. (a) The impact of donor/recipient ratio on pCTgfp
transmission. Each data point is the mean from four biological replicates; each data set comprises four independent
experiments. (b) The impact of 6 mM linoleic acid, 3.5 mg/ml ascorbic acid, or 20 g/ml chlorpromazine on pCTgfp
transmission in B104 populations. Data show the mean  standard deviation from four independent experiments,
each with four biological replicates. *, P 0.05; **, P 0.001, calculated using Student’s t test.
Compounds Reduce AMR Plasmid Transmission ®
January/February 2020 Volume 11 Issue 1 e03355-19 mbio.asm.org 9
 o
n
 M
ay 18, 2020 by guest
http://m
bio.asm
.org/
D
ow
nloaded from
 
There was a large reduction in the number of pKpQIL K. pneumoniae transconju-
gants formed in the presence of 0.008 to 0.25 g/ml AZT (Fig. 6d); 0.25 g/ml AZT
reduced transconjugants by 80.8%  3.4% of LB controls (P 0.0001). The MICs of AZT
for the K. pneumoniae strains were 4 and 2 g/ml for the Ecl8 parental strain and Ecl8
pKpQILgfp, respectively, and the MIC was 16 g/ml for Ecl8 mcherry. We consistently
saw variation in the MIC between biological replicates within each experiment, with
sporadic mutants appearing in wells with higher concentrations of AZT. In order to
quantify this observation, we determined the mutation frequency of E. coli and K.
pneumoniae strains to AZT (Table S2), which ranged from 8.65 107 to 1.45 106.
This is in line with the observations of others (67, 68, 71, 73). Ecl8 mcherry grew more
FIG 6 Abacavir and AZT impact AMR plasmid transmission. (a) pCTgfp transmission in ST131c EC958 E. coli after
24-h incubation with abacavir. (b) pKpQILgfp transmission in K. pneumoniae after 6-h incubation with abacavir. (c)
pCTgfp transmission in ST131c EC958 E. coli after 24-h incubation with AZT. (d) pKpQILgfp transmission in K.
pneumoniae after 6-h incubation with AZT. (e) AZT impact on transmission in AZT-resistant mutants of E. coli
ST131c. ST131c pCTgfp and ST131c mcherry mutants were selected on 16 g/ml AZT. Data show the mean 
standard deviation from a minimum of three independent experiments, each with at least three biological
replicates. *, P 0.05; **, P 0.001, calculated using Student’s t test.
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quickly at 0.016 and 0.032 g/ml AZT, while above 0.12 g/ml, AZT inhibited growth
(Fig. S2d and e). Ecl8/pKpQILgfp grew more slowly at0.06 g/ml AZT (Fig. S2d and e).
At the lowest concentrations tested (0.008 to 0.032 g/ml), there was no effect on
growth of donors or recipients and these concentrations significantly reduced pKpQIL
transmission (Fig. 6d).
AZT is a prodrug which is activated within the cell by phosphorylation events
mediated by thymidine kinase to produce AZT-triphosphate, the active component in
DNA chain termination (74). Single point mutations in thymidine kinase can result in
AZT resistance (68, 73). Therefore, to determine if AZT-triphosphate was the active
antiplasmid compound, we selected AZT-resistant E. coli mutants after exposure to
16 g/ml AZT for 24 h. The mutation frequency to AZT (Table S2) was typical of that
associated with a mutation in a single gene. The MIC of AZT for the mutants was
32 g/ml. Sequencing of the thymidine kinase gene revealed a 10-bp deletion. The
AZT-resistant mutants were then used in AZT transmission assays. AZT had no effect on
plasmid transmission in the AZT-resistant mutants (Fig. 6e). This indicates that the
active antiplasmid component is AZT-triphosphate.
DISCUSSION
In this study, the dynamics of two globally disseminated, clinically relevant plasmids,
producing either an ESBL or carbapenemase, were monitored for transmission in near
real time into E. coli and K. pneumoniae populations, respectively. With fluorescently
labeled plasmids and recipient bacteria, we monitored plasmid transmission among
populations using flow cytometry.
We showed that chlorpromazine and linoleic acid function as inhibitors of an IncK
CTX-M-producing plasmid transfer in E. coli and that chlorpromazine also functions as
an antiplasmid compound for the IncFII KPC-producing plasmid pKpQIL in K. pneu-
moniae. Ascorbic acid had little/no effect on plasmid transmission, despite having a
strong impact on bacterial growth. This shows that compounds that decrease growth
do not necessarily also reduce plasmid transmission. While a variety of factors, includ-
ing growth rate and low-level antibiotic selection, can impact the frequency of plasmid
transfer (75, 76), we did not see such impact with ascorbic acid. Much of the work
demonstrating the antiplasmid activity of ascorbic acid has been done with Gram-
positive bacteria (45–47) and not Gram-negative bacteria as used here.
Chlorpromazine is a bioactive molecule which has many effects on the bacterial cell
(63). These include intercalation into DNA molecules and possible breaks in single-
stranded DNA (ssDNA) (77, 78). This intercalation could prevent the replication of the
plasmid, resulting in plasmid loss from a population of bacteria. Chlorpromazine
integrates into the lipid bilayer, impacting membrane permeability, fluidity, and some
membrane-associated proteins (79–81). For example, chlorpromazine disrupted the
activity of membrane-associated ATPases (82, 83). One can speculate that chlorprom-
azine may impact either the plasmid DNA itself, or the activity of the ATPases involved
in the type IV secretion system used for conjugation, and thus inhibit plasmid trans-
mission.
Here, we show that linoleic acid effectively inhibited conjugation of the IncK plasmid
pCT at 24 h but had no impact on the IncFII plasmid pKpQIL in K. pneumoniae. Linoleic
acid has previously been shown to inhibit conjugation of some plasmids, including IncF
and IncW (48). Linoleic acid prevents conjugation by inhibiting the activity of the R388
plasmid TrwD ATPase, which is a type IV secretion traffic ATPase, and a homologue of
Agrobacterium tumefaciens VirB11 (49, 84). The pCT plasmid encodes an ATPase in trbB
(5), which in the plasmid RP4 encodes a homologue of VirB11 (85). Therefore, we
hypothesize that the pCT TrbB is the target of linoleic acid-mediated transmission
inhibition.
There was good correlation between the pCT flow cytometry data and the
classical conjugation data. Both assays show that linoleic acid had the strongest
antiplasmid activity, followed by chlorpromazine, AZT, and then abacavir. Interest-
ingly, ascorbic acid reduced the conjugation frequency in classical conjugation
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experiments, but this was not detected in the ST131c flow cytometry experiments.
It may be that the low level of activity of ascorbic acid is near the limit of detection
of the flow cytometry assay. We hypothesize that any discrepancy between the
conjugation assay and the flow cytometry assay may also relate to the large
variation between conjugation assay experiments. Overall, the flow cytometry assay
is optimal for medium-high-throughput experiments to identify compounds that
inhibit plasmid transmission.
The flow cytometry assay was used to screen in medium throughput (hundreds of
compounds/week) for compounds/drugs that inhibited transmission of pCT and pK-
pQIL within two species of bacteria. The two most promising hits from the Prestwick
library were abacavir and AZT. While the impact of abacavir was modest, AZT had
potent activity. These compounds have very different chemical structures from conju-
gation inhibitors such as linoleic acid and chlorpromazine. Abacavir and AZT are
nucleoside analogue prodrugs that inhibit reverse transcriptase activity and are used
clinically to treat HIV infection (see Table S1 in the supplemental material) (74, 86–88).
AZT is converted into the active metabolite AZT-5=-triphosphate by thymidine kinases
(67, 68), which is incorporated into DNA in place of thymidine, but since AZT lacks the
3=-hydroxy group, it results in chain termination (74). In the 1980s, AZT (2 g/ml) was
shown to inhibit the growth of E. coli and K. pneumoniae; however, AZT-resistant
mutants with mutations in thymidine kinase were easily isolated in vitro (67); we made
a similar observation in this study. Furthermore, AZT-resistant E. coli and Salmonella
were recovered from patients receiving AZT treatment for HIV infection (89, 90).
Recently, and in light of growing AMR, the antimicrobial properties of AZT have been
explored (68–71, 73).
We hypothesize that the mechanism of antiplasmid activity of abacavir and AZT is
that these compounds interfere with plasmid replication, including DNA chain termi-
nation, thus reducing plasmid transfer and/or plasmid presence in the population. This
would explain our conjugation frequency data, which showed a smaller reduction in
conjugation frequency in the presence of AZT than suggested by flow cytometry at the
same concentration. Thus, when AZT reduces plasmid prevalence within the bacterial
population, a substantial portion of cells may have lost the plasmid with the selectable
marker (aph) used to distinguish donor/recipient/transconjugant bacteria; thus, in
conjugation experiments such cells would skew the calculations used to determine
conjugation frequency.
Two independent screens of FDA-approved compound libraries identified AZT as
having activity against drug-resistant Gram-negative bacterial isolates (69, 70) and
obtained MICs of AZT similar to those found in our study. The concentrations required
to kill bacteria are within the peak serum concentrations for the drug (Table S1), and the
use of already-approved drugs as new antibacterial compounds is attractive, as much
of the pharmacokinetics (PK) and safety profiles are well established (74). In a study on
human intestinal flora, 20 M AZT affected growth of 10 bacteria including some strains
of Bacteroides, Bifidobacterium, Clostridium, Odoribacter, Roseburia, and E. coli (91). Maier
et al. (91) also estimated the intestinal concentrations of abacavir and AZT to be around
150 M and 374 M, respectively. These concentrations are much higher than the
plasma concentrations of both drugs (Table S1) and, importantly, much higher than the
concentrations which have antiplasmid properties. The concentration at which we
saw antiplasmid activity (8 g/ml abacavir corresponds to 27.9 M; 0.008 g/ml
AZT corresponds to 0.029 M) is within this range. Drug accumulation in the gut is
ideal for an antiplasmid compound, as the intestinal flora is considered to be a hot
spot for horizontal gene transfer, and dosage could be minimized, thus reducing
potential systemic adverse effects. AZT treatment for HIV infection can result in
AZT-resistant bacteria (89, 90). However, since the concentration which inhibits
AMR plasmids is low (	1/512 the MIC), the use of low doses as antiplasmid
strategies would minimize the selection of resistant mutants. Furthermore, it is
possible that although resistant bacteria could be selected at higher concentra-
tions, such bacteria may no longer harbor plasmids carrying ARGs. To explore this
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hypothesis, clinical isolates of AZT-resistant bacteria should be examined for the
presence of plasmids.
AMR plasmids are frequently found in the normal bacterial flora, in particular in the
gastrointestinal (GI) tract (10, 11, 18–20, 41, 42). While it is clear that AMR plasmids are
found and can persist within the GI tract, details of the intricacies of the AMR
plasmid-microbiome relationships are still unclear. The impact of antiplasmid com-
pounds on the AMR plasmid-microbiome relationship, including the impact of
plasmid copy number and evolution, remains to be elucidated. However, we
anticipate that improved models of AMR plasmid dynamics in the microbiome will
allow the opportunity to address the impact of these factors on antiplasmid
compound efficacy. In future, the testing of compounds such as abacavir and AZT
in multispecies experiments will provide important insight into potential pathogen-
microbiome interactions.
Before antiplasmid compounds can be used to reduce AMR prevalence in
bacterial populations, additional factors should be considered. These include the
potential differential activities of compounds on different plasmids and hosts. As
shown here, compound activity may not be ubiquitous against all plasmids/
bacteria. Furthermore, clinical strains can contain multiple plasmids; the impact of
compounds in these settings should be examined. In complex, multispecies envi-
ronments, plasmid-containing strains may also form the minority within the pop-
ulation; therefore, impact of compounds on minority populations and plasmid-free
cells should be considered.
Additional chemical modifications and/or homologues may improve the anti-
plasmid activity and/or reduce antibacterial properties of abacavir and AZT, thus
improving activity and alleviating any potential for selection pressure for AZT
resistance. The use of nontoxic compounds to limit the spread of AMR plasmids (as
opposed to killing the bacteria and thus reducing selective pressure) in key areas
where transmissible ARGs are prevalent could be an effective means of reducing
critical AMR in bacteria.
Identification of antiplasmid compounds has been slow, in large part due to
dependence upon laborious plating experiments, which are not amenable to medium-/
high-throughput screening. Apart from one screening system for conjugation inhibitors
(48, 92, 93), most studies of antiplasmid compounds have used classical conjugation
experiments. We developed and applied a fluorescence-based assay to monitor the
movement of globally prevalent plasmids associated with human infections in two
different Gram-negative species with plasmids carrying ESBL or carbapenemase genes.
Furthermore, we used this assay in a medium-throughput screen and identified novel
antiplasmid compounds. We uncovered the antiplasmid properties of two currently
licensed and widely used anti-HIV drugs, abacavir and AZT. In light of the challenges
associated with developing new antibiotics, nucleoside analogue drugs could be used
to reduce the prevalence of drug-resistant Gram-negative bacteria via decolonization of
vulnerable patients so that if they succumb to an infection a currently licensed drug will
be effective.
MATERIALS AND METHODS
Bacterial strains, growth, and measurement of drug susceptibility. The ST131 strain EC958 was
isolated from a patient with a community-acquired UTI in Northwest England and has been used as a
representative of this clonal group (50, 51). It is a multidrug-resistant (MDR) strain, carrying a pEK499-like
136-kb plasmid, pEC958 (50, 51). pEC958 is an IncF plasmid with two replicons, RepFII and RepFIA, and
12 resistance genes, including CTX-M-15 (55). The pKpQIL plasmid was used as previously described
(termed pKpQIL-UK in publications [38, 94]). Repeated attempts to establish the fluorescent system in K.
pneumoniae from the ST258 lineage were unsuccessful. Therefore, we used K. pneumoniae Ecl8, which
has been used previously (38, 53, 54) by others and ourselves for successful cloning applications. Details
regarding sequencing, culture conditions, growth kinetics assays, MIC assays, and pEC958 curing can be
found in Text S1 and the list of plasmids, strains, and primers can be found in Table S3, both in the
supplemental material.
Construction of gfp reporters. pCTCTX-M-14 was previously modified by insertion of gfp-aph under
the control of the acpP promoter into blaCTX-M and stored in E. coli DH5 (95). Filter matings (per
reference 38) were used to move pCTgfp from DH5 into ST131c, the variant of ST131 EC958 cured using
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an incompatibility system (courtesy of Christopher M. Thomas), and transconjugants were selected on
256 g/ml nalidixic acid and 75 g/ml kanamycin. Plasmid presence was confirmed by PCR, and host
strain identity was confirmed by testing ciprofloxacin resistance, confirming previously reported MIC
values (55), and whole-genome sequencing (WGS; details available in Text S1). Expression of gfp was
confirmed by flow cytometry, as described below.
For pKpQILgfp construction, pUA66 was used as the template, and PCR was used to amplify gfp-mut2
under the control of the acpP promoter with aph located downstream of gfp-mut2. E. coli SW105
containing temperature-sensitive recombinase and pKpQIL was made electrocompetent, and gfp-mut2
PCR product was transformed into the cells. Successful insertions were selected on kanamycin (50 g/ml)
and confirmed by PCR and sequencing. The constructed plasmid pKpQILgfp was transformed into E. coli
DH10B for long-term storage. K. pneumoniae Ecl8 was made electrocompetent, and pKpQILgfp was
transformed into cells, selected for using 50 g/ml kanamycin, and confirmed by PCR and sequencing.
Expression of GFP was confirmed by flow cytometry.
Construction of mCherry-expressing recipient strains. To prepare the mcherry fragment, the acpP
promoter was amplified from pUA66 (L1019), using primers with HindIII and BamHI sites; this was then
digested and inserted into mcherry encoding pET-17b. This resulted in pET-17b pacpP-mcherry. The aph
cassette was amplified from pKD4, with primers inserting XhoI sites up- and downstream of the gene.
Restriction digestion and ligation were carried out to insert aph downstream of mcherry. PCR was used
to confirm the direction of the aph cassette, and the final construct (pET-17b pacpP-mcherry-aph) was
confirmed by PCR and sequencing. PCR was used to amplify the pacpP-mcherry-aph region, with primers
containing a 45-bp overlap corresponding to the putPA intergenic region in E. coli or K. pneumoniae.
putPA was chosen because this locus has been previously shown to minimize impact and allow
expression of fluorescent proteins (56).
The pSIM18 plasmid, expressing recombinase machinery under a temperature-sensitive promoter
(96), was transformed into electrocompetent E. coli or K. pneumoniae. pSIM18-containing colonies were
selected using 150 g/ml hygromycin at 30°C. Expression of the recombinase machinery was induced,
and pSIM18 cells were made electrocompetent; the pacpP-mcherry-aph PCR product was transformed
into these cells. After recovery at 37°C, cells were subcultured on plates containing 50 g/ml kanamycin.
Successful insertion events were identified by PCR amplification of the inserted region, and loss of
hygromycin resistance (pSIM18) was tested. Expression of mcherry was confirmed by flow cytometry, as
described below.
Construction of fluorescent reporters in E. coli ST131 B104. A naturally plasmid-free E. coli ST131
clinical isolate, B104 (52), was modified for use in the pCT transmission assay. First, to construct the B104
donor strain, a rifampin-resistant B104 strain was generated by overnight growth on LB agar containing
100 g/ml rifampin. Candidate colonies were selected, and growth kinetics were determined to ensure
that mutation did not impact growth rate. Sequencing of the rpoB gene was performed to identify the
mutations resulting in rifampin resistance. Then, conjugation was used to move pCTgfp from ST131c
pCTgfp into B104RifR, resulting in the construction of B104 pCTgfp. PCR was used to confirm the presence
of pCTgfp, and flow cytometry was used to check fluorescence.
To construct the B104 recipient strain, the recombineering plasmid pSLTS (97) was first transformed
into B104 by electroporation, as described above. PCR was used to amplify the pacpP-mcherry-aph region
from pET-17b pacpP-mcherry-aph, with primers containing a 45-bp overlap corresponding to the putPA
intergenic region in B104. This product was transformed into electrocompetent B104 pSLTS, similar to
what is described above and according to reference 97. Successful recombination events were selected
on 50 g/ml kanamycin. PCR was used to confirm insertion of mcherry, and flow cytometry was used to
check fluorescence.
Transmission assay. Overnight cultures of donor (E. coli with pCTgfp or K. pneumoniae with
pKpQILgfp) and recipients (E. coli or K. pneumoniae with chromosomal mcherry) were washed in
phosphate-buffered saline (PBS) (Sigma) and diluted to an optical density (600 nm) of 0.5. Bacteria were
combined at a donor/recipient ratio of 3:1 for E. coli and 1:2 for K. pneumoniae, unless otherwise specified.
This mixture (20 l) was used to inoculate 180 l of LB broth in a 96-well plate. Controls included LB
broth alone, donor alone, and recipient alone. The plate was incubated at 37°C with gentle agitation
(	80 rpm) for the specified amount of time. At each time point, 20 l was removed and serially diluted
to 1:1,000 in PBS filtered through 0.2-m filters. Samples were run on the Attune NxT acoustic focusing
flow cytometer with Autosampler (Thermo Scientific), equipped with a blue/yellow (excitation laser:
blue, 488 nm; yellow, 561 nm) laser configuration; additional details can be found in Text S1. Flow
cytometry has been previously used to monitor plasmids within populations (for examples, see
references 98 and 99).
Ascorbic acid, chlorpromazine, linoleic acid, abacavir, and AZT were added to LB in 96-well plates,
over a range of concentrations. Ascorbic acid stock solutions of 100 mg/ml were prepared in sterile
distilled water, chlorpromazine stock solutions of 10,000 g/ml were prepared in water, linoleic acid
stock solutions of 100 mM were prepared in 30% dimethyl sulfoxide (DMSO), abacavir sulfate stock
solutions of 10,000 g/ml were prepared in water, and AZT stock solutions of 1,000 g/ml were prepared
in methanol. All transmission assays were completed with a minimum of three independent experiments,
with between three and four biological replicates per experiment.
For pCTgfp transmission in B104 strains, transmission assays were set up exactly as described above,
with different donor/recipient ratios tested. Antiplasmid compounds were tested at the following
concentrations: 3.5 mg/ml ascorbic acid, 6 mM linoleic acid, and 20 g/ml chlorpromazine.
Details of how conjugation frequencies were determined can be found in Text S1.
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Determining frequency of mutation for AZT resistance and selection of AZT-resistant mutants.
To determine AZT frequency of mutation, ST131c, ST131 pCTgfp, and ST131 mcherry were plated onto
LB agar plates containing 16 g/ml AZT and LB agar plates containing no drug. Plates were incubated
for 24 h at 37°C, and the colonies were enumerated. The Don Whitley Scientific automated spiral plater
was used, per the manufacturer’s instructions. For each strain, 4 biological and 5 technical replicates were
used. Mutation frequency was calculated by dividing the number of mutants by the viable count. From
the AZT plates, mutant colonies were selected, and the MIC of AZT was determined as indicated above.
Candidates with an AZT MIC of32 g/ml were selected, and the thymidine kinase gene was sequenced
to determine if mutations had occurred (primers listed in Table S3). Mutants with deletions in thymidine
kinase were then used in the AZT flow cytometry assay.
Fluorescent microscopy. Multichannel confocal images were taken at the Birmingham Light Ad-
vance Microscopy (BALM) facility at the University of Birmingham. In order to allow a proper comparison
between different samples, the same optical configuration (digital zoom, photomultiplier tube [PMT],
laser power, Galvano scanner, and pinhole) was used in all acquisitions. Samples were mixed to a final
volume of 6 l in morpholinepropanesulfonic acid (MOPS) minimal medium alone or with ascorbic acid
(3.5 mg/ml), linoleic acid (6 M), or chlorpromazine (50 g/ml). A higher chlorpromazine concentration
was used because of the short duration of this experiment. Bacteria were mounted on a conventional
glass slide, placed on a heated stage (37°C), and immediately imaged every 10 min over 120 min.
Time-lapse acquisition was performed sequentially by using the 488-nm and the 543-nm laser lines on
a Zeiss LSM710 Confocor3 point scanning confocal system mounted on an Axio Observer inverted
microscope with a 63/1.4 oil objective (Zeiss).
Image analysis was performed on the open-source software ICY (http://icy.bioimageanalysis.org/)
using the Wavelet Spot Detector and the Colocalization Studio plugins to assess the level of colocaliza-
tion between the two different cells over time. A total of 12 images across 3 replicates for each time point
and condition were analyzed. The number of colocalization events was normalized to the total number
of bacteria and plotted using GraphPad Prism.
High-throughput screening. The Prestwick Chemical Library, containing 1,280 drugs and com-
pounds, was tested in 96-well format using a Hamilton Star robot to identify compounds which inhibited
the transmission of pCTgfp in ST131c or pKpQIL in K. pneumoniae. Compounds were dissolved in DMSO.
A final concentration of 10 M compound was added to the assay plate containing LB broth and a 3:1
or 1:2 mixture of donor and recipient cells (as described above). The final concentration of DMSO was
tested and had no impact on bacterial growth or plasmid transmission. Plates were incubated for 24 h
and read on the Attune flow cytometer as described above. The OD600 of each plate was determined
using a FLUOstar Optima, as described above. Each compound plate was repeated in two independent
experiments. Plates containing promising compounds were repeated a third time. The number of
transconjugants in each well was determined and compared with LB controls. Compounds with levels of
transmission below LB values were considered possible hits.
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